Myovant Sciences is a healthcare company dedicated to revolutionizing women's and men's healthcare with its lead product candidate, relugolix. This once-daily, oral GnRH receptor antagonist has had success in late-stage clinical programs for the treatment of uterine fibroids, endometriosis, and prostate cancer. The company is also working on MVT-602, an oligopeptide kisspeptin-1 receptor agonist, for the treatment of female infertility. Myovant has a worldwide license from Takeda Pharmaceuticals, except for Japan and certain other Asian countries, to develop and commercialize relugolix, and an exclusive license for MVT-602. The majority shareholder of Myovant is Sumitovant Biopharma, Ltd., a subsidiary of Sumitomo Dainippon Pharma Co., Ltd.